Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin and Efgartigimod Alfa in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States (P10-11.028)
This study aimed to project the budget impact of introducing efgartigimod alfa in a proportion of CIDP patients currently receiving SCIG and IVIG.
Authors
- Rashad Carlton
- Joris van Stiphout
- Betsy J. Lahue (ORCID: https://orcid.org/0000-0002-8659-1336)
- Rajiv Mallick (ORCID: https://orcid.org/0000-0002-0273-9680)
- Alphonse P. Hubsch (ORCID: https://orcid.org/0000-0001-7139-0526)
Institutions
- Alkem (India) (IN)
- CSL (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210672
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00